$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
肾癌患者服用索拉非尼的药物剂量
2025-10-19 11:44:20
Check Details
卡博替尼一线治疗晚期肾细胞癌
2025-10-19 11:44:20
Check Details
依维莫司治疗晚期肾细胞癌患者
2025-10-19 11:44:20
Check Details
卡博替尼 vs 舒尼替尼一线治疗中低风险转移性肾细胞癌:CABOSUN试验生存期数据更新
2025-10-19 11:44:20
Check Details
多吉美治疗肾癌推荐剂量是多少?
2025-10-19 11:44:20
Check Details
卡博替尼+奥希替尼治疗继发克唑替尼耐药MET突变的肺腺癌
2025-10-19 11:44:20
Check Details
卡博替尼治疗放射学进展性甲状腺髓样癌: III期EXAM研究最新数据
2025-10-19 11:44:20
Check Details
卡博替尼用于晚期肾癌患者的一线治疗
2025-10-19 11:44:20
Check Details
奥希替尼和舒尼替尼那个治疗肾癌效果好
2025-10-19 11:44:20
Check Details
舒尼替尼一线治疗晚期RCC的疗效
2025-10-19 11:44:20
Check Details
舒尼替尼与Keytruda+Inlyta组合治疗肾癌的疗效
2025-10-19 11:44:20
Check Details
舒尼替尼治疗中国晚期肾癌患者
2025-10-19 11:44:20
Check Details
1
2
...
8177
8178
8179
8180
8181
8182
8183
...
10233
10234
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Etrasimod for Ulcerative Colitis: 2mg Once Daily, Onset Timeline, and Safety Monitoring
2
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
3
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
4
Post-Enzalutamide mCRPC: HRR/PARP, PSMA Radioligand, and Chemotherapy Sequencing
5
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
6
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
7
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
8
Bedaquiline for Drug-Resistant TB: 24-Week Regimen, Combination Duration, and When to Stop or Extend
9
Acalabrutinib Dosing and Combination Regimens: CLL/SLL, MCL, Safety Adjustments
10
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
11
Bosutinib for Ph+ CML: Indications, Dosing Adjustments, and Hepatic/Renal Safety
12
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks